Participated · Series A · Nov 2022

Micron Biomedical develops a dissolvable microarray-based, needle-free platform for administration of drugs and vaccines. Its proprietary technology is designed to enable injection-free, painless and simple or self-administration, and to reduce or eliminate cold-chain requirements. The platform aims to enhance safety and efficacy while improving patient compliance. The company is led by CEO Steve Damon and is based in Atlanta, GA. Micron intends to use newly raised funds to expand operations and its R&D sector. Financially, the company extended its Series A to over $33M following the latest financing. Micron Biomedical is a clinical-stage life science company developing dissolvable microarray-based products for injection-free, painless administration of drugs and vaccines. Its core product is a microarray technology that reduces or eliminates cold chain requirements and enables community health workers to vaccinate quickly by applying a patch and pressing a button to confirm administration. Micron reported successful phase I/II clinical data in the Gambia across adults, toddlers, and infants as young as nine months using a leading commercial measles-rubella vaccine delivered via its microarray. The company plans to build a commercial-scale manufacturing facility—funded by a $23.6M Gates Foundation grant—to mass-produce needle-free vaccines and support larger clinical trials and regulatory approvals. Micron’s technology aims to expand vaccine access in low- and middle-income countries, improve patient acceptance in higher-income markets, and strengthen US national, veteran, and military health. Micron partners with the Bill & Melinda Gates Foundation, the CDC, PATH, and the Georgia Research Alliance and previously received a Gates grant in 2017 that enabled its first pediatric clinical trial. Micron Biomedical is an Atlanta-based life sciences company advancing dissolvable microarray-based drug and vaccine administration technology. Its patented microarray technology enables drugs and vaccines that today require cold storage and injection to be self-administered or caregiver-administered within minutes without refrigeration or a skilled health professional. The company aims to bring its dissolvable microarray products to markets globally. Micron has partnered with or received funding from private and public pharmaceutical and biotech companies as well as the Bill & Melinda Gates Foundation, the CDC, UNICEF, PATH and the Georgia Research Alliance. The company is led by CEO Steven Damon. The Series A extension will further support commercialization and global market efforts. Micron Biomedical is a clinical-stage life sciences company advancing its Micro Array Patch (MAP) technology to enable self-administration and less-skilled caregiver administration of drugs and vaccines without needles. Led by CEO Steven Damon and based in Atlanta, GA, the company’s pipeline includes vaccine and drug products partnered with pharmaceutical companies, foundations, and government agencies. Micron has demonstrated clinical efficacy for its MAP technology and since inception has supported R&D with more than $40 million in non-dilutive financing. The company intends to use the new funds to develop commercial manufacturing capacity, which is currently underway. Micron has received support and funding from foundations and public health organizations that have partnered on development and trials.

Participated · Seed · Feb 2022

Altesa BioSciences is focused on treating chronic lung diseases by targeting the viral infections that trigger respiratory exacerbations. Its lead oral candidate, vapendavir, is designed to neutralise rhinovirus—the predominant cause of exacerbations in millions of COPD and asthma patients. In a recently completed Challenge Study, vapendavir improved upper and lower airway symptoms, shortened illness duration, lowered inflammatory markers, and preserved small-airway function relative to placebo. The company projects that, if approved, vapendavir could prevent up to 50 % of COPD exacerbations, improving quality of life and reducing healthcare costs. Altesa plans to launch the 900-patient Phase 2b CARDINAL study in the US and UK in Q2 2026 to further evaluate safety and efficacy. Led by former U.S. Assistant Secretary of Health Brett P. Giroir, M.D., and guided by a board chaired by Moncef Slaoui, Ph.D., the team includes seasoned executives with backgrounds at GSK and other major firms. The firm is headquartered in Atlanta and advocates for expanded access to modern respiratory diagnostics and therapeutics in underserved communities.

Participated · Series B · Feb 2022

Codoxo offers a Generative AI-powered Unified Cost Containment Platform that spans the entire claim lifecycle, with its flagship Point Zero Payment Integrity model intervening before claims are even submitted. By combining proactive provider education, data mining, clinical chart review, deepfake detection, and policy-to-code automation, the platform reduces downstream denials and overpayments while strengthening payer–provider relationships. The company supports payment integrity operations across more than 80 million covered lives and reports 100 % customer retention and 125 % net revenue retention for 2025. Customer implementations have delivered $12–$16 PMPY in savings at the pre-claim stage and up to $66 PMPY across the broader payment spectrum. Codoxo has earned recognition from Inc. 5000, Everest Group, Black Book Research, and the A.I. Awards, underscoring its category leadership. Recent product launches include the Data Health Integrity Agent and generative-AI-driven Policy-to-Code capabilities. With continued compliance achievements such as NIST 800-53 Rev 5 and HITRUST r2 certification, Codoxo is positioning itself for accelerated national expansion.

Participated · Series B · Nov 2021

Antios is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases, with a lead program targeting chronic HBV. Its lead candidate, ATI-2173, is a once-daily oral investigational phosphoramidate prodrug of clevudine monophosphate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development. ATI-2173 is in Phase 2b development and is being evaluated in the SAVE-1 trial, a double-blind, randomized, placebo-controlled study of 30 patients testing 25 mg and 50 mg doses daily for 90 days in combination with tenofovir disoproxil fumarate (TDF). Preclinical data and Phase 1b results indicate potent on-treatment and durable off-treatment HBV DNA suppression and that the drug has been generally well-tolerated. The company plans to advance ATI-2173 through Phase 2b and further clinical development toward a potential curative once-daily HBV regimen. The recent $75 million financing strengthens Antios's financial position to support these clinical programs. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases. Its lead candidate, ATI-2173, is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) designed to deliver the 5'-monophosphate of clevudine to the liver. ATI-2173 is described as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site, producing potent antiviral activity and extended off-treatment suppression of HBV DNA. The company plans to advance ATI-2173 through a Phase 2 clinical program to evaluate its potential as the backbone of a once-daily curative regimen for chronic hepatitis B. Antios reported potent on-treatment and durable off-treatment effects in a Phase 1b study, with those results slated for presentation at an upcoming medical conference. To support development, Antios completed a $96 million Series B financing. Antios Therapeutics is an Atlanta, GA–based biopharmaceutical company focused on developing novel antiviral therapies for unmet medical needs. Its lead oral candidate, ATI-2173, is being advanced as part of a curative regimen for chronic hepatitis B virus (HBV) and potentially hepatitis D virus (HDV). The company targets chronic HBV, which affects over 250 million people worldwide and is a leading cause of chronic hepatitis, liver cirrhosis and liver cancer. Antios is led by co-founders Abel De La Rosa (CEO) and Douglas Mayers (CMO). The company intends to use proceeds from its recent financing to continue development of ATI-2173. The article does not disclose revenue or user metrics.

Led · Seed · Jul 2017

Carbice develops carbon nanotube-based thermal management products designed to improve heat transfer at the chip level for high-performance electronics. The company reports commercial deployments of its products in laptops, servers and satellites. Founder and CEO Baratunde Cola has spent more than 15 years developing the underlying technology and six years building the business into a thermal management company serving multiple industries. Carbice says it operates what it describes as the world’s largest aligned carbon nanotube manufacturing facility and plans to accelerate production to meet demand. The company positions its technology as a response to growing cooling constraints in data centers driven by AI adoption and rising compute demand. The article does not provide revenue, user, or valuation metrics.